ketanserin has been researched along with Arteriosclerosis Obliterans in 4 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of ketanserin treatment (40 mg daily for 90 days) was evaluated in 88 patients with arterial hypertension combined with Leriche-Fontaine stage II obliterating arterial disease of the lower limbs." | 9.07 | [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin]. ( Mollo, P, 1991) |
| "Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors." | 6.66 | Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. ( Abrignani, MG; Adamo, L; Alaimo, G; Avellone, G; Cutietta, A; Giordano, U; Indovina, A; Novo, S; Pinto, A; Strano, A, 1986) |
| "The efficacy of ketanserin treatment (40 mg daily for 90 days) was evaluated in 88 patients with arterial hypertension combined with Leriche-Fontaine stage II obliterating arterial disease of the lower limbs." | 5.07 | [Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin]. ( Mollo, P, 1991) |
| "Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors." | 2.66 | Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. ( Abrignani, MG; Adamo, L; Alaimo, G; Avellone, G; Cutietta, A; Giordano, U; Indovina, A; Novo, S; Pinto, A; Strano, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerritsen, HA | 1 |
| Perquin, JW | 1 |
| de Smet, HL | 1 |
| Troost, FA | 1 |
| Kotora, OV | 1 |
| Mollo, P | 1 |
| Regenthal, R | 1 |
| Voigt, H | 1 |
| Novo, S | 1 |
| Alaimo, G | 1 |
| Abrignani, MG | 1 |
| Giordano, U | 1 |
| Avellone, G | 1 |
| Pinto, A | 1 |
| Adamo, L | 1 |
| Cutietta, A | 1 |
| Indovina, A | 1 |
| Strano, A | 1 |
1 review available for ketanserin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[The clinical significance of serotonin antagonists].
Topics: Arteriosclerosis Obliterans; Humans; Hypertension; Ischemia; Ketanserin; Leg; Serotonin Antagonists | 1989 |
2 trials available for ketanserin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Essential arterial hypertension and Leriche-Fontaine stage II obliterating vascular disease of the lower limbs. A new pharmacological approach with ketanserin].
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Female; Humans; Hypertension; Ketanserin; Leg; | 1991 |
Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Coagulation; Blood Pressure; Doub | 1986 |
1 other study available for ketanserin and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Continuous imaging of regional blood flow in peripheral vascular disease using Krypton-81m: effect of Ketanserin, a new selective serotonin antagonist.
Topics: Animals; Arteriosclerosis Obliterans; Cats; Diabetic Angiopathies; Female; Humans; Hyperemia; Ketans | 1983 |